Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children
Liyuan Chen, Fen Liu, Danna Fang, Jianwei Li · 2023
Read Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children by Liyuan Chen, Fen Liu, Danna Fang, Jianwei Li (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10725990.txt.
Description
Liyuan Chen, Fen Liu, Danna Fang, and Jianwei Li reviewed real-world results for the drug nusinersen in children with spinal muscular atrophy, types two and three. The drug is still fairly new, and most data came from trials. The team studied records of eighteen children treated in twenty twenty-two and twenty twenty-three.
After the loading doses, arm and hand scores improved in nearly half the children. Those who improved most also showed a bigger rise in a key protein in spinal fluid. Liver tests stayed steady. Blood platelet counts and urine protein dipped at times but recovered. The authors call the drug effective and broadly safe, with checks still needed.
Catalog record
| CREATOR | Liyuan Chen, Fen Liu, Danna Fang, Jianwei Li |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |